BSF Enterprise PLC (LSE:BSFA, OTC:BSFAF), the biotechnology company focused on tissue engineering, traded at 1.39p, up 20.87% in early London trading.
The surge followed the announcement of a partially binding strategic partnership with SCHAKAU Managementberatung GmbH to target the luxury automotive and advanced robotics markets.
The German consultancy will provide direct commercial conduits into European ultra-luxury vehicle manufacturers.
Initial commercialisation will focus on high-margin, bespoke interior trim and steering elements using BSF's lab-grown leather.
The bespoke approach generates early commercial traction without requiring immediate large-scale industrial manufacturing infrastructure.
The partnership also aims to supply bio-engineered human skin equivalents as biological surface layers for humanoid and industrial robotic systems.
These advanced biological surface layers are designed to provide natural flexibility and structural compatibility that traditional synthetic outer layers cannot match.
The six-year commercial model includes a revenue share mechanism for all programmes originated by SCHAKAU.
The agreed baseline revenue share applies in full for the first three years following initial commercial production.
This allocation reduces by 50% for the subsequent three years and then ceases entirely.
The framework contemplates a milestone-based equity and option programme that is entirely contingent upon defined commercial targets.
A sliding scale success fee applies to any capital introduced by SCHAKAU, starting at 5% for sums up to £10 million.
BSF retains absolute ownership of all underlying patents, scaffolds, trade secrets, and cell-manufacturing workflows.
SCHAKAU receives exclusivity for opportunities it introduces, subject to a withdrawal clause activated by 180 consecutive days without substantive commercial interaction.
The partners are targeting binding agreements for both the automotive and robotics sectors by January 2027.